Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways

Endocrine

Volumn 53, Issue 1, 2016, Pages 107-116

  Tang, Song tao ^a   Zhang, Qiu ^a   Tang, Hai qin ^a   Wang, Chang jiang ^a   Su, Huan ^a   Zhou, Qing ^a   Wei, Wei ^a   Zhu, Hua qing ^a   Wang, Yuan ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Advanced glycation endproducts; Endothelial function; Glucagon like peptide 1; Nuclear factor B

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; RHO KINASE; SITAGLIPTIN; STREPTOZOCIN; ADENYLATE KINASE; INCRETIN; PEPTIDE; REACTIVE OXYGEN METABOLITE; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; INFLAMMATION; LIPID DIET; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; AORTA; BLOOD; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM;

ADENYLATE KINASE; ANIMALS; AORTA; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; ENDOTHELIUM, VASCULAR; GLUCAGON-LIKE PEPTIDE 1; GLYCOSYLATION END PRODUCTS, ADVANCED; INCRETINS; MALE; NF-KAPPA B; NITRIC OXIDE; OXIDATIVE STRESS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; SITAGLIPTIN PHOSPHATE; VENOMS;

EID: 84954308309     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0852-y     Document Type: Article

References (39)

1. S. Rahbar, Novel inhibotrs of glycation and AGE formation. Cell Biochem. Biophys. 48, 147–157 (2007)
2. M. Brownlee, A. Cerami, A. Vlassara, Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318, 1315–1321 (1998)
3. S.F. Yan, R. Ramasamy, A.M. Schmidt, The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res. 106, 842–853 (2010)
4. S. Yamagishi, K. Nakamura, T. Matsui, Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharmacol. Res. 60, 174–178 (2009)
5. S. Yamagishi, T. Imaizumi, Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 11, 2279–2299 (2005)
6. K. Jandeleit-Dahm, M.E. Cooper, The role of AGEs in cardiovascular disease. Curr. Pharm. Des. 14, 979–986 (2008)
7. S. Yamagishi, K. Nakamura, T. Matsui, S. Ueda, K. Fukami, S. Okuda, Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin. Investig. Drugs 17, 983–996 (2008)
8. U. Chakravarthy, R.G. Hayes, A.W. Stitt, E. McAuley, D.B. Archer, Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 47, 945–952 (1998)
9. P. Quehenberger, A. Bierhaus, P. Fasching, C. Muellner, M. Klevesath, M. Hong et al., Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49, 1561–1570 (2000)
10. F.L. Zhan, H.Q. Gao, J.M. Wu, Y.B. Ma, B.A. You, B.Y. Li et al., Selective inhibition by grape seed proanthocyanidin extracts of cell adhesion molecule expression induced by advanced glycation end products in endothelial cells. J. Cardiovasc. Pharmacol. 48, 47–53 (2006)
11. H. Okamoto, T. Yoshio, H. Kaneko, H. Yamanaka, Inhibition of NF-kappaB signaling by fasudil as a potential therapeutic strategy for rheumatoid arthritis. Arthritis Rheum. 62, 82–92 (2010)
12. Y. Lu, H. Li, W. Jian, J. Zhuang, K. Wang, W. Peng et al., The Rho/Rho-associated protein kinase inhibitor fasudil in the protection of endothelial cells against advanced glycation end products through the nuclear factor κB pathway. Exp Ther Med. 6, 310–316 (2013)
13. D.J. Drucker, Glucagon-like peptides. Diabetes 47, 159–169 (1998)
14. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, M. Husain, Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 118, e81 (2008)
15. T. Nyström, M.K. Gutniak, Q. Zhang, F. Zhang, J.J. Holst, B. Ahrén et al., Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 287, E1209–E1215 (2008)
16. Y. Hattori, T. Jojima, A. Tomizawa, H. Satoh, S. Hattori, K. Kasai et al., A glucagon-like peptide-1(GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 53, 2256–2263 (2010)
17. Y. Dai, J.L. Mehta, M. Chen, Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc. Drugs Ther. 27, 371–380 (2013)
18. B. Zhou, Y. Pan, Z. Hu, X. Wang, J. Han, Q. Zhou et al., All-trans-retinoic acid ameliorated high fat diet-induced atherosclerosis in rabbits by inhibiting platelet activation and inflammation. J Biomed Biotechnol. 2012, 259693 (2012)
19. B. Picatoste, E. Ramírez, A. Caro-Vadillo, C. Iborra, S. Ares-Carrasco, J. Egido et al., Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS ONE 8, e78330 (2013)
20. N. Panjwani, E.E. Mulvihill, C. Longuet, B. Yusta, J.E. Campbell, T.J. Brown et al., GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 154, 127–139 (2013)
21. S. Del Turco, G. Basta, An update on advanced glycation endproducts and atherosclerosis. BioFactors 38, 266–274 (2012)
22. B. Xu, Y. Ji, K. Yao, Y.X. Cao, A. Ferro, Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin. Sci. (Lond.) 109, 439–446 (2005)
23. P.C. Chang, Y.H. Chen, C.J. Chang, C.C. Hou, P. Chan, H.M. Lee, Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int. 65, 1664–1675 (2004)
24. Y.W. Yoon, T.S. Kang, B.K. Lee, W. Chang, K.C. Hwang, J.H. Rhee et al., Pathobiological role of advanced glycation endproducts via mitogen-activated protein kinase dependent pathway in the diabetic vasculopathy. Exp. Mol. Med. 40, 398–406 (2008)
25. V. Rajapurohitam, A. Kilic, S. Javadov, M. Karmazyn, Role of NF-κB and p38 MAPK activation in mediating angiotensin II and endothelin-1-induced stimulation in leptin production and cardiomyocyte hypertrophy. Mol. Cell. Biochem. 366, 287–297 (2012)
26. A. Piechota, A. Goraca, Influence of nuclear factor-κB inhibition on endothelin-1 induced lung edema and oxidative stress in rats. J. Physiol. Pharmacol. 62, 183–188 (2011)
27. Y. Hattori, S. Hattori, N. Sato, K. Kasai, High-glucose-induced nuclear factor kappaB activation in vascular smooth muscle cells. Cardiovasc. Res. 46, 188–197 (2000)
28. W.S. Yang, J.W. Seo, N.J. Han, J. Choi, K.U. Lee, H. Ahn et al., High glucose-induced NF-kappaB activation occurs via tyrosine phosphorylation of I kappa B alpha in human glomerular endothelial cells: involvement of Syk tyrosine kinase. Am J Physiol Renal Physiol. 294, F1065–F1075 (2008)
29. F.A. Cicek, H.B. Kandilci, B. Turan, Role of ROCK upregulation in endothelial and smooth muscle vascular functions in diabetic rat aorta. Cardiovasc Diabetol. 12, 51 (2013)
30. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, M. Husain, Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117, 2340–2350 (2008)
31. M.H. Noyan-Ashraf, E.A. Shikatani, I. Schuiki, I. Mukovozov, J. Wu, R.K. Li et al., A glucagon-like Peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 127, 74–85 (2013)
32. F. Vittone, A. Liberman, D. Vasic, R. Ostertag, M. Esser, D. Walcher et al., Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia 55, 2267–2275 (2012)
33. Z. Shah, T. Kampfrath, J.A. Deiuliis, J. Zhong, C. Pineda, Z. Ying et al., Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124, 2338–2349 (2011)
34. L. Han, Y. Yu, X. Sun, B. Wang, Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways. Diabetes Res. Clin. Pract. 97, 453–460 (2012)
35. Y. Ishibashi, T. Matsui, M. Takeuchi, S. Yamagishi, Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun. 391, 1405–1408 (2010)
36. Y. Ishibashi, T. Matsui, M. Takeuchi, S. Yamagishi, Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm. Metab. Res. 43, 731–734 (2011)
37. D. Wang, P. Luo, Y. Wang, W. Li, C. Wang, D. Sun et al., Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes 62, 1697–1708 (2013)
38. G.P. Fadini, E. Boscaro, M. Albiero, L. Menegazzo, V. Frison, S. de Kreutzenberg et al., The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 33, 1607–1609 (2010)
39. Y. Hu, H. Liu, R.W. Simpson, A.E. Dear, GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells. Mol. Biol. Rep. 40, 2273–2279 (2013)